Study on the mechanism of action of platinib under RET gene-related mutations

The RET gene, as a proto-oncogene that may be rearranged during transfection, is closely related to the occurrence of many types of tumors. In these tumors, mutations or fusions of the RET gene may lead to uncontrolled cell proliferation, thereby promoting tumor formation and development. Targeting this key target, platinib, as a highly effective RET inhibitor, has demonstrated significant clinical effects.

The mechanism of action of Platinib is mainly reflected in the selective inhibition of RET kinase activity. It can dose-dependently inhibit the phosphorylation of RET and its downstream molecules, thereby effectively blocking cell proliferation signals driven by RET gene mutations. This highly specific inhibitory effect enables platinib to accurately attack tumor cells while reducing its toxic side effects on normal cells.

In the context of RET gene-related mutations, the targeted therapeutic effect of platinib is particularly prominent. Whether it is a RET fusion gene mutation or a RET point mutation, Platinib can block the growth and spread of tumor cells by inhibiting the activity of RET kinase. Especially in tumors with a high incidence of RET gene mutations, such as non-small cell lung cancer and medullary thyroid cancer, the clinical application of platinib has achieved remarkable results.

It is worth mentioning that platinib has also shown potential in overcoming resistance to traditional therapeutic drugs. Since mutations in the RET gene may cause tumor cells to become resistant to traditional drugs, targeted therapy targeting the RET gene has become an effective solution. As a new type of RET inhibitor, platinib not only performs well in the treatment of treatment-naïve patients, but also provides a new treatment option for patients who have received other treatments and developed resistance.